Compare Research Peptides

Select 2 peptides to compare benefits, dosage, administration routes, mechanisms, and side effect profiles side by side.

Peptide 1

Peptide 2

	PT-141 Bremelanotide Sign up to track	Kisspeptin-10 Metastin Sign up to track
Evidence Grade	AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved	BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries
Regulatory	FDA ApprovedFDA ApprovedApproved by the US Food and Drug Administration for at least one indication	Research OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only
Category	Sexual Health & Libido	Sexual Health & Libido
Key Benefits	•Treats sexual dysfunction in men and women •Enhances arousal and desire •Works via central nervous system (not vascular like Viagra) •FDA-approved for female HSDD +2 more	•Increases testosterone naturally •Enhances libido •Improves fertility markers •May increase LH and FSH +2 more
Dosage	1-2 mg mg	1-2 mcg mcg
Frequency	As needed, 45 minutes before sexual activity	Daily or as needed
Administration	SubcutaneousIntranasal	SubcutaneousIntranasal
Mechanism	PT-141 (Bremelanotide) is a melanocortin receptor agonist that works on the central nervous system to enhance sexual arousal and desire. It is FDA-approved for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.	Kisspeptin-10 is a neuropeptide that regulates reproductive hormone secretion. It stimulates GnRH, leading to LH and FSH release, and may enhance libido and sexual function.
Side Effects / Risks	Not specified	Not specified
Research Status	FDA-approved for female hypoactive sexual desire disorder (Vyleesi)	Research compound - clinical trials